Kumate J

Language: Spanish
References: 16
Page: 397-406
PDF size: 133.94 Kb.

Text Extraction

No abstract

REFERENCES

1. Chaves S, et al. Loss of vaccine induced immunity to varicella over time. N Engl J Med. 2007; 356: 1121-9.

2. Halstead SB. Dengue. Lancet. 2007; 370: 1644-652.

3. Hulid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008; 371: 932-44.

4. Linhares A, et al. Efficacy and safety of an oral attenuated rotavirus vaccine. Lancet. 2008; 371: 1181-9.

5. Mc Aleer W, Hillerman MR. Human hepatitis B vaccine from recombinant yeast. Nature. 1984; 307: 178-80.

6. MMWR. Mumps epidemic-United Kingdom 2004-2005. MMWR. Morb Mortal Wkly Rep. 2006; 55: 173-5.

7. Pizza M, et al. Mutants of pertussis toxin suitable for vaccine development. Science. 1989; 246: 497-500.

8. Plotkin SA. Six revolutions in vaccinology. Pediatr Infect Dis J. 2005; 24.

9. Plotkin SA. Vaccine: past, present and futures. Nature Med. 2005; 11: 55-511.

10. Popov-Kraupp T, et al. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe A and Jeryl Lynn-Moraten) in young children. J Med Virol. 1986; 18: 69-79.

11. Roush SW, et al. Historical comparisons of morbility and mortality for vaccine-preventable diseases in the United States. JAMA. 2007; 298: 2155-63.

12. Runowinz CD. Molecular screening for cervical cancer: time to give up Pap. Test? N Engl J Med. 2007; 357: 1650-65.

13. Schneerson R, Robbins JB. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980; 152: 361-76.

14. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccinations. Pediatr Infect Dis J. 1991; 10: 209-28.

15. Theiler M, Smith NN. The use of yellow fever vaccines by in vitro cultivation for humans immunizations. J Exp Med. 1937; 65: 787-800.

16. 2nd WHO Consultation. Update of an avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008; 358: 261-73.